Range Nuclear Renaissance ETF vs GeneDx Holdings Corp — how do they compare? Range Nuclear Renaissance ETF trades at $61.26 (market cap $698.21M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.9× Range Nuclear Renaissance ETF's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Range Nuclear Renaissance ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Range Nuclear Renaissance ETF for 18 Days and GeneDx Holdings Corp for 19 Days on average.
| NUKZ | WGS | |
|---|---|---|
Market Cap | $698.21M | $2.02B |
Volume | 57,444 | 734,640 |
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $167.51 |
52-Week Low | $60.23 | $34.51 |
Typical Hold Time | 18 Days | 19 Days |
Enterprise Value | — | $2.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →